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Abstract 
Bone involvement is uncommon in epithelial ovarian cancer. In this report, a case of 
bone metastases from ovarian cancer is described and the potential risk factors for such 
a rare occurrence are discussed. It is possible that such an event will become more 
common in the future as patients with advanced ovarian cancer experience prolonged 
survival but the cancer is not eliminated. 
 
Introduction 
Bone involvement in epithelial ovarian cancer is very unusual, with several series 
noting an incidence of <2% [1, 2]. A recently encountered ovarian cancer patient who was 
found to have significant bone involvement at the time of disease recurrence, after an 
extended treatment-free interval, emphasizes the potential risk of metastatic disease in 
such sites and suggests possible unique features associated with this event. 
Case Report 
A 60-year-old female with a history of epithelial ovarian cancer was seen for a second opinion 
concerning management. She had originally been diagnosed with, and treated for, this malignancy in 
1998. Following initial surgery and chemotherapy, the patient remained without evidence of disease 
until 2007 when documented recurrence within the peritoneal cavity led to an attempt at secondary 
surgical cytoreduction. This was followed by chemotherapy including both carboplatin and 
gemcitabine. The patient experienced considerable bone marrow suppression from this regimen, 
presumably due (at least in part) to the residual effects of her prior chemotherapy. Case Rep Oncol 2011;4:490–491 
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The patient subsequently remained well until the fall of 2010 when she developed both lower pelvic and 
back pain. A pelvic PET/CT scan revealed a pre-sacral mass with definite erosion of the cancer into the 
sacrum. The bony involvement was confirmed on a follow-up MRI scan. The mass was felt to be 
unresectable and a decision was made to initially treat her with a platinum-based combination 
chemotherapy program (carboplatin plus pegylated liposomal doxorubicin), and to then consider surgery 
or local radiation therapy (depending on the impact of the response to the cytotoxic therapeutic regimen). 
Discussion 
One of the remarkable features of epithelial ovarian cancer is its localization in most 
patients to the peritoneal cavity during the majority of its natural history, despite potentially 
quite large tumor volumes contained within this region of the body [3]. It has been 
hypothesized that successful spread of the malignancy requires a variety of essential specific 
growth factors and nutrients found within the peritoneal cavity and peritoneal fluid. 
However, it is also well recognized that women with advanced ovarian cancer who 
experience more prolonged survival have a greater likelihood of experiencing metastatic 
spread to additional locations, such as the central nervous system [1, 2]. It is possible that 
late-developing malignant clones have lost the essential requirement for external growth 
factor support in order to become established in distant sites. It is also reasonable to 
hypothesize that these cancers have been present, but quiescent, in these regions of the 
body for long periods before they become clinically evident. The patient presented in this 
report was known to have had epithelial ovarian cancer for 12 years prior to the 
documentation of metastatic spread to the bone, an observation consistent with other 
reports of the development of bone involvement as a late metastatic event in the natural 
history of the malignancy [1, 2, 4–6]. 
It is relevant for clinicians caring for ovarian cancer patients to appreciate that 
although bone is a most unusual initial site of metastatic spread in this setting, bony 
involvement may become a more common feature in the increasing proportion of 
patients with this malignancy who are expected to experience extended survival (>4–5 
years) but who, unfortunately, are not expected to be cured of the disease process [7]. 
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